Skip to content

Ranibizumab

Lucentis (ranibizumab) is an antibody pharmaceutical. Ranibizumab was first approved as Lucentis on 2006-06-30. It is used to treat diabetic retinopathy, macular edema, and retinal vein occlusion in the USA. It has been approved in Europe to treat degenerative myopia, diabetes complications, diabetic retinopathy, macular edema, and wet macular degeneration. The pharmaceutical is active against vascular endothelial growth factor A.
Trade Name Lucentis
Common Name Ranibizumab
Indication degenerative myopia, diabetes complications, diabetic retinopathy, macular edema, retinal vein occlusion, wet macular degeneration
Drug Class Monoclonal antibodies
Ranibizumab
Get full access now